Abstract 480P
Background
EGFR-mutant NSCLC patients(pts) have various types of co-mutation, such as TP53. Co-mutations contribute to high tumor heterogeneity in early NSCLC, potentially resulting in different clinical outcomes of resectable NSCLC. However, the impact of clinical benefit in pts with EGFR co-mutation in the ADAURA study remains unclear. Our study aimed to investigate the efficacy of the third-generation EGFR-TKI aumolertinib as adjuvant therapy for stage I-III EGFR-mutant NSCLC underwent R0 resection, and the impact of co-mutations on the clinical benefit.
Methods
We enrolled EGFR-mutant NSCLC pts who underwent radical surgery and received a daily dose of aumolertinib 110 mg. The duration of adjuvant therapy depended on the pts’pathologic stage and physical conditions. We evaluated the disease-free survival (DFS) and safety ,including the efficacy of aumolertinib in pts with co-mutation.
Results
This study retrospectively analyzed 91 cases of pathologically confirmed adenocarcinoma, EGFR positive mutation (19Del or L858R), and stage I-III NSCLC pts from August 2021 to August 2023. At the data cut-off, all pts have no symptoms of tumor recurrence. 62 pts (68.1%) have been followed up for ≥ 6 months, 27 pts (29.7%) have been followed up for ≥ 12 months. The 1-year DFS rate is 100%.
Among them, 35 pts had EGFR co-mutation and 48.5% was with TP53 co-mutation. Median age was 59 years and 74.3% were female. 17 pts (48.6%) have been followed up for ≥ 6 months, 7 pts (20%) have been followed up for ≥ 12 months. At 12 months, 100% pts were alive and disease-free, consistent with the overall population. There was no difference in postoperative recurrence between the co-mutation and the overall population currently. No grade≥3 adverse events occurred. The common adverse events were mild rash and diarrhea. No pts withdrew from therapy due to adverse drug reactions.
Conclusions
This study demonstrated the significant efficacy of aumolertinib as adjuvant therapy for completely resected stage I-III EGFR-mutated NSCLC, and reported the consistent efficacy of aumolertinib in pts with co-mutation for the first time. Our study is still ongoing to expand the cohort of pts with co-mutation and extend the follow-up period to determine longer-term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract